Literature DB >> 15622609

Challenges in the epidemiological and clinical aspects of Burkitt's lymphoma in Kenya: linking evidence and experience.

O W Mwanda1, R Rochford, J Rainey, M L Wilson.   

Abstract

BACKGROUND: In a series of 1005 cases of Burkitt's lymphoma studied for epidemiological and clinical characteristics, some features remain less obvious contrary to what is commonly held about this disease.
OBJECTIVES: To use the case series to document the challenges in the epidemiological and clinical characteristics of Burkitt's lymphoma (BL) in Kenya.
DESIGN: Cross sectional study involving clinical review of case series.
SETTING: Kenyatta National Hospital and the seven provincial hospitals in Kenya during the period between 1986 and 1996. DATA SOURCES: Systematic review of the epidemiological and clinical features of the 1005 cases enrolled in the case study and review of reference lists of retrieved articles to identify original research dealing with the epidemiological and clinical features of Burkitt's lymphoma. DATA EXTRACTION: The investigators and research assistants screened both the case series and published information and data to yield relevant information.
CONCLUSION: The majority of Burkitt's lymphoma cases between the age group three and nine years of age coincide with the established epidemiological and clinical characteristics. The adult BL cases and some childhood cases however do not conform entirely to the established characteristics. Therefore, making the diagnosis of Burkitt's lymphoma require that; geographical, demographical, clinical features as well as any underlying infections for instance, Human Immunodeficiency Virus be taken into consideration.

Entities:  

Mesh:

Year:  2004        PMID: 15622609     DOI: 10.4314/eamj.v81i8.9215

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  5 in total

1.  Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.

Authors:  Christopher C Stanley; Kate D Westmoreland; Brett J Heimlich; Nader K El-Mallawany; Peter Wasswa; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Mary Chikasema; Victor Makwakwa; Bongani Kaimila; Edwards Kasonkanji; Fred Chimzimu; Coxcilly Kampani; Bal M Dhungel; Robert Krysiak; Nathan D Montgomery; Yuri Fedoriw; Nora E Rosenberg; N George Liomba; Satish Gopal
Journal:  Br J Haematol       Date:  2016-02-23       Impact factor: 6.998

2.  Quantifying bias in survival estimates resulting from loss to follow-up among children with lymphoma in Malawi.

Authors:  Christopher C Stanley; Kate D Westmoreland; Salama Itimu; Ande Salima; Toon van der Gronde; Peter Wasswa; Idah Mtete; Mercy Butia; Nader K El-Mallawany; Satish Gopal
Journal:  Pediatr Blood Cancer       Date:  2016-11-28       Impact factor: 3.167

3.  Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.

Authors:  Amolo S Asito; Erwan Piriou; Peter Sumba Odada; Nancy Fiore; Jaap M Middeldorp; Carole Long; Sheetij Dutta; David E Lanar; Walter G Jura; Collins Ouma; Juliana A Otieno; Ann M Moormann; Rosemary Rochford
Journal:  Infect Agent Cancer       Date:  2010-07-28       Impact factor: 2.965

4.  Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi.

Authors:  Christopher C Stanley; Toon van der Gronde; Kate D Westmoreland; Ande Salima; Amy Amuquandoh; Salama Itimu; Agness Manda; Idah Mtete; Mercy Butia; Atupele Mpasa; Stella Wachepa; Paula Fox; Peter Wasswa; Peter Kazembe; Nader K El-Mallawany; Satish Gopal
Journal:  Support Care Cancer       Date:  2017-10-07       Impact factor: 3.603

5.  Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma.

Authors:  Cliff I Oduor; Mercedeh Movassagh; Yasin Kaymaz; Kiprotich Chelimo; Juliana Otieno; John M Ong'echa; Ann M Moormann; Jeffrey A Bailey
Journal:  Front Microbiol       Date:  2017-03-28       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.